

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07H 21/04, C12Q 1/68, C07K 5/00	A3	(11) International Publication Number: WO 99/60986 (43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number: PCT/US99/11743 (22) International Filing Date: 27 May 1999 (27.05.99) (30) Priority Data: 09/085,199 27 May 1998 (27.05.98) US (71) Applicants (for all designated States except US): UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; University Industry Liaison Office, IRC Building - Room 331, 2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3 (CA). MERCK FROSST CANADA & CO. [CA/CA]; PO/CP 1005, Pointe Claire-Dorval, Québec H9R 4P8 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): KALCHMAN, Michael [CA/CA]; #1403-900 Yonge Street, Toronto, Ontario M4W 3P5 (CA). HAYDEN, Michael, R. [US/CA]; 4484 West Seventh, Vancouver, British Columbia V6R 1W9 (CA). HACKAM, Abigail [CA/CA]; 1420 West 11th Avenue, Vancouver, British Columbia V6H 1L2 (CA). CHOPRA, Vikramjit [CA/CA]; Suite 210, 2475 Blenheim Street, Vancouver, British Columbia V6K 4N7 (CA). NICHOLSON, Donald, W. [CA/CA]; 18-750 Milton Street, Montréal, Québec H2X 1W4 (CA). VALLAINCOURT, John, P. [CA/CA]; 18022 Amalfi Street, Québec, Québec H9K 1N7	(CA). RASPER, Dita, M. [CA/CA]; Apartment #7, 16203 Pierrefonds Boulevard, Pierrefonds, Québec H9H 4S8 (CA). (74) Agent: COPPOLA, Joseph, A.; Merck & Co., Inc., P.O. Box 2000, Rahway, NJ 07065-0907 (US). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 20 April 2000 (20.04.00)	
(54) Title: APOPTOSIS MODULATORS THAT INTERACT WITH THE HUNTINGTON'S DISEASE GENE		
(57) Abstract <p>A family of proteins, including a specific human protein designated as HIP1, has been identified that interact differently with the gene product of a normal (16 CAG repeat) and an expanded (>44 CAG repeat) HD gene. Expression of the HIP1 protein was found to be enriched in the brain. Analysis of the sequence of the HIP1 protein indicated that it includes a death effector domain (DED), suggesting an apoptotic function. Thus, it appears that a normal function of Huntingtin may be to bind HIP1 and related apoptosis modulators, reducing its effectiveness in stimulating cell death. Since expanded huntingtin performs this function less well, there is an increase in HIP1-modulated cell death in individuals with an expanded repeat in the HD gene. This understanding of the likely role of huntingtin and HIP1 or related proteins (collectively "HIP-apoptosis modulating proteins") in the pathology of Huntington's disease offers several possibilities for therapy. First, because the function of huntingtin apparently depends at least in part on the ability to interact with HIP-apoptosis modulating proteins, added expression (e.g., via gene therapy) of normal (non-expanded) huntingtin or of the HIP-binding region of huntingtin should provide a therapeutic benefit. Other DED-interacting peptides could also be used to mask and reduce the interaction of HIP-apoptosis modulating proteins with the death signaling complex. Alternatively, a mutant form of HIP-protein from which the DED has been deleted might be introduced, for example using gene therapy techniques. Because HIP-apoptosis modulating proteins have been shown to self-associate, a protein with a deleted DED may compete with endogenous HIP-protein in the formation of these associations, thereby reducing the amount of apoptotically-active HIP-protein.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/11743

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C07H 21/04; C12Q 1/68; C07K 5/00

US CL : 536/23.5; 435/6; 530/350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.5; 435/6; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

USPAT, CAPLUS, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WANKER et al., HIP-I: A Huntingtin Interacting Protein Isolated by the Yeast Two-hybrid System. Human Molecular Genetics. March 1997, Vol. 6, No. 3, pages 487-495, see entire document.	1-15

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

B earlier document published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

A document member of the same patent family

Date of the actual completion of the international search

20 DECEMBER 1999

Date of mailing of the international search report

3 February 2000 (03.02.00)

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

SCOTT HOUTTEMAN

Telephone No. (703) 308-0196

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
 United States Patent and Trademark
 Office
 Box PCT
 Washington, D.C. 20231
 ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 08 March 2000 (08.03.00)	
International application No. PCT/US99/11743	Applicant's or agent's file reference UBC.P-013WO2
International filing date (day/month/year) 27 May 1999 (27.05.99)	Priority date (day/month/year) 27 May 1998 (27.05.98)
Applicant KALCHMAN, Michael et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

13 December 1999 (13.12.99)

☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
 34, chemin des Colombettes
 1211 Geneva 20, Switzerland

Authorized officer

Juan Cruz

Facsimile No.: (41-22) 740.14.35

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

REC'D 25 SEP 2000

PCT

WIPO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference MC010-PCT	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US99/11743	International filing date (day/month/year) 27 MAY 1999	Priority date (day/month/year) 27 MAY 1998
International Patent Classification (IPC) or national classification and IPC IPC(7): CO7H 21/04; C12Q 1/68; C07K 5/00 and US Cl.: 536/23.5; 435/6; 530/350		
Applicant [MERCK FROSST CANADA AND CO.] * UNIVERSITY OF BRITISH COLUMBIA.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 4 sheets.
- ☒ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 3 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 13 DECEMBER 1999	Date of completion of this report 15 AUGUST 2000
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231	Authorized officer <i>Scott Houtteman</i> SCOTT HOUTTEMAN
Facsimile No. (703) 305-3230	Telephone No. (703) 308-0196

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/11743

I. Basis of the report

1. With regard to the elements of the international application:*

☐ the international application as originally filed☒ the description:

pages (See Attached)

, as originally filed

pages , filed with the demand

pages , filed with the letter of

☒ the claims:

pages (See Attached)

, as originally filed

pages , as amended (together with any statement) under Article 19

pages , filed with the demand

pages , filed with the letter of

☒ the drawings:

pages (See Attached)

, as originally filed

pages , filed with the demand

pages , filed with the letter of

☒ the sequence listing part of the description:

pages (See Attached)

, as originally filed

pages , filed with the demand

pages , filed with the letter of

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).☐ the language of publication of the international application (under Rule 48.3(b)).☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

☒ contained in the international application in printed form.☒ filed together with the international application in computer readable form.☐ furnished subsequently to this Authority in written form.☐ furnished subsequently to this Authority in computer readable form.☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.4. ☒ The amendments have resulted in the cancellation of:☒ the description, pages NONE☒ the claims, Nos. 7-8, 10-11☒ the drawings, sheets/fig NONE5. ☒ This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/11743

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. statement**

Novelty (N)	Claims <u>1-6, 9, 12-15</u>	YES
	Claims <u>NONE</u>	NO
Inventive Step (IS)	Claims <u>1-6, 9, 12-15</u>	YES
	Claims <u>NONE</u>	NO
Industrial Applicability (IA)	Claims <u>1-6, 9, 12-15</u>	YES
	Claims <u>NONE</u>	NO

2. citations and explanations (Rule 70.7)

Claims 1-6, 9, 12-15 meet the criteria set out in PCT Article 33(2)-(4). The closest prior art Wanker et al. teach an HD-interacting polypeptide expression vector. Wanker et al., however, does not teach or fairly suggest the claimed HD interacting protein encoded by SEQ ID NOS. 2, 4 5 or 7 nor the methods of use of HD interacting proteins in reducing apoptosis or in screening for apoptosis inhibiting activity.

----- NEW CITATIONS -----
NONE

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/11743

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

I. BASIS OF REPORT:

This report has been drawn on the basis of the description,
page(s) 1-31, as originally filed.
page(s) NONE, filed with the demand.
and additional amendments:
NONE

This report has been drawn on the basis of the claims,
page(s) NONE, as originally filed.
page(s) NONE, as amended under Article 19.
page(s) NONE, filed with the demand.
and additional amendments:
Pages 32-33, filed with the letter of 15 August 2000.

This report has been drawn on the basis of the drawings,
page(s) 1-12, as originally filed.
page(s) NONE, filed with the demand.
and additional amendments:
NONE

This report has been drawn on the basis of the sequence listing part of the description:
page(s) 1-44, as originally filed.
pages(s) NONE, filed with the demand.
and additional amendments:
NONE

5. (Some) amendments are considered to go beyond the disclosure as filed:
NONE

CLAIMS

- 1 1. A polypeptide comprising the sequence given by Seq. ID. No. 5.
- 1 2. A cDNA molecule comprising the sequence given by Seq. ID No. 6.
- 1 3. A polypeptide comprising the sequence given by Seq. ID No. 7.
- 1 4. A method for ameliorating the effects of Huntington's disease in a
2 patient expressing a HIP-apoptosis modulating protein, comprising the step of administering
3 the patient a therapeutic composition which reduces the activity of the HIP-apoptosis
4 modulating protein.
- 1 5. A method according to claim 4, wherein the composition comprises a
2 material which binds to HIP-apoptosis modulating protein.
- 1 6. The method according to claim 4, wherein the composition comprises
2 an expression vector encoding huntingtin having a normal number of repeats.
- 1 7. An expression vector for expression of a gene in a mammalian host
2 comprising a region encoding an HD-interacting polypeptide.
- 1 8. The expression vector according to claim 7, wherein the HD-
2 interacting polypeptide is an HIP-apoptosis modulating protein.
- 1 9. The expression vector according to claim 8, wherein the HIP-apoptosis
2 modulating protein has a sequence which includes the amino acid sequences given by SEQ
3 ID Nos. 2, 4, 5 or 7.

REPLACED BY
ART 34 AMDT

1 10. The expression vector of claim 7, wherein the HD-interacting
2 polypeptide interacts differently with expanded Huntingtin than with Huntingtin having a
3 CAG repeat region containing 15 to 35 repeats.

1 11. The expression vector according to claims of claims 7-10, further
2 comprising a region encoding Huntingtin having a polyglutamine tract of 35 or fewer.

1 12. A method for inducing apoptotic death in cells, comprising the step of
2 introducing into the cells an expression vector encoding at least the death effector domain of
3 a HIP-apoptosis modulating protein whereby the death effector domain is expressed by the
4 cells.

1 13. The method of claim 12, wherein the expression vector encodes the
2 amino acid sequence given by Seq. ID. No. 2.

1 14. The method of claim 12, wherein the expression vector encodes the
2 amino acid sequence given by Seq. ID. No. 4.

1 15. A method for screening a composition for the ability to inhibit
2 apoptosis induced by an HIP-apoptosis modulating protein, comprising simultaneously
3 exposing a population of cells to the composition and an HIP-apoptosis modulating protein
4 and measuring the extent of cell death.

REPLACED BY
ART 34 ANDT

PATENT COOPERATION TREATY
PCT

NOTE ON INFORMAL COMMUNICATION WITH THE APPLICANT

(PCT Rule 66.6)

International application No. PCT/US99/11743	Applicant's or agent's file reference MC010-PCT	Date of informal communication (day/month/year) 15 AUGUST 2000
Applicant MERCK FROSST CANADA AND CO.,		


<u>Communication</u> <input checked="" type="checkbox"/> by telephone <input type="checkbox"/> personal	<u>Participants</u> <input type="checkbox"/> Applicant: <input checked="" type="checkbox"/> Agent: Mr. Joseph A. Coppola <input checked="" type="checkbox"/> Examiner(s): SCOTT HOUTTEMAN	<input checked="" type="checkbox"/> identity checked	<input type="checkbox"/> authorization checked	<input type="checkbox"/> personally known
-----------------------------------------------------------------------------------------------------------------------	----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------	------------------------------------------------	-------------------------------------------

Summary of communication:

The examiner and the applicant's rep. agreed to claim amendments.

☐ An extension of time limit is granted (Form PCT/IPEA/427).

☒ A copy of this note is being sent to the applicant with Form PCT/IPEA/429.
PCT/IPEA/424.

Applicant/Agent Mr. Joseph A. Coppola	Authorized officer of IPEA/US  SCOTT HOUTTEMAN Telephone No. (703) 308-0196
----------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------------